Drug firm Aurobindo Pharma Thursday said its step-down subsidiary has received a warning letter from the US health regulator for its unit in New Jersey, US.
Aurobindo Pharma on Tuesday said the US health regulator has decided that the inspection classification of company's injectable formulation manufacturing facility at Hyderabad is voluntary action indicated (VAI).
Drug firm Aurobindo Pharma on Friday said the US health regulator has revoked the voluntary action initiated (VAI) status for its Unit-IV facility in Hyderabad.
New Delhi: Aurobindo Pharma is all set to acquire troubled US-based nutritional supplement maker, Natrol Inc for USD 132.5 million (over Rs 810 crore) after emerging as the highest bidder for acquisition.Aurobindo Pharma USA Inc,
New Delhi: Aurobindo Pharma today reported 58.3 per cent jump in consolidated net profit at Rs 372.2 crore for the quarter ended September on the back of robust growth in the US market.The company had
New Delhi: The MSCI Global Standard Indices will see the addition of Aurobindo Pharma with effect from May 30.The change will take place as on close of May 30, MSCI had said on Wednesday. Shares of
New Delhi, June 28: Drug firm Aurobindo Pharma has said it has received tentative approval from the US health regulator to manufacture and market efavirenz, lamivudine and tenofovir disoproxil fumarate tablets used for treating a
New Delhi, April 30:Aurobindo Pharma Ltd has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Quinapril tablets. The tablet is generic equivalent of Pfizer Pharmaceuticals Ltd's Accupril tablets and
Top News
Latest News
